PharmTech News

Feliza Mirasol is the science editor for 

Articles

FDA's approval makes Orchard Therapeutics' Lenmeldy (atidarsagene autotemcel) the first gene therapy approved to treat pediatric metachromatic leukodystrophy in the US.

FDA Greenlights Orchard Therapeutics' Gene Therapy for Children's MLD; AGC Biologics Selected for Manufacturing

Mapp Biopharmaceutical will use ProBioGen’s GlymaxX technology for the development of an afucosylated antibody against Marburg virus infection

Mapp Biopharmaceutical Teams Up with ProBioGen and to Develop Antibody Against Marburg Virus Disease

The European company has seen its business increase by 47% in North America.

Bormioli Pharma’s Business Expands in United States

EMA has validated two MAAs submitted by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan in two types of cancer.

EMA Validates Parallel Applications for Datopotamab Deruxtecan in Two Types of Cancer

The facility producer’s new innovation hub will offer manufacturing, life sciences, and infrastructure services.

Jacobs Announces Innovation Hub in Denmark

EMA plans to add 10 partners to its real-world data initiative, DARWIN EU, in 2024.

Europe's DARWIN EU Data Program Adds Capacity

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.

AstraZeneca Set to Boost the UK’s Life Sciences Sector with Investment Plans

The company is expanding GMP capacities at its Frankfurt site to manufacture early clinical-phase peptide APIs.

CordenPharma Expands Clinical Peptide Capacity

Wider life sciences industries in the UK and Europe are receiving favourable financial support from governing bodies.  

Budget Benefit

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Steffen Thirstrup, chief medical officer, EMA, emphasizes the importance of transparency in investigating potential safety issues of CAR-T therapies, while highlighting the need to balance regulatory diligence with maintaining trust within the community and among stakeholders.

PharmTech Europe News